Psychosocial impact of onychomycosis: a review

Chacon, Anna; França, Katlein; Fernandez, Alexandra A; Nouri, Keyvan

doi:10.1111/ijd.12122

Cited by 34 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Onychomycosis is a common infectious disease, which if inappropriately treated can lead to spread of the infection, complications, diminished patient quality of life and may result in stigmatization [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay

Ghannoum

Sevin

Sarkany

2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionOnychomycosis is the most common infectious disease involving nails. The aim of this study was to evaluate the antifungal activity of amorolfine 5% nail lacquer and three different acid-based medical devices indicated in the treatment of onychomycosis using an in vitro nail penetration assay.MethodsFour products were tested in vitro: (a) amorolfine 5% nail lacquer; (b) ethyl lactate and acetic acid; (c) citric acid and urea; (d) ethyl lactate, glycerin, lactic acid, and citric acid. Test products were applied to healthy human cadaver nails and allowed to dry. Disks were cut from each piece of nail and placed on seeded agar plates of Trichophyton rubrum. Following incubation at 30 °C, zones of inhibition were measured.ResultsAmorolfine-treated nails exhibited inhibitory activity against T. rubrum with a mean zone of inhibition of 59.2 mm in diameter. In contrast, all three acid-based medical devices and the untreated controls showed no zones of inhibition (mean effective zones of 0 mm).ConclusionIn this in vitro nail penetration model, head-on, comparative study, we showed that amorolfine 5% nail lacquer possesses potent antifungal activity, whereas no antifungal activity was detected for three commercially available acid-based medical devices under identical assay conditions.FundingGalderma.Electronic supplementary materialThe online version of this article (doi:10.1007/s13555-016-0093-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay

Ghannoum

Sevin

Sarkany

2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Multiple studies report the presence of anxiety and depression associated with onychomycosis along with low body image and self-esteem, which in turn deteriorates one’s sense of worth [30-33]. Affected persons may additionally be less willing to participate in social and leisure activities, furthering the already deteriorated mental state [34].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature

Gupta

Mays

2018

Skin Appendage Disord

View full text Add to dashboard Cite

Purpose: Onychomycosis is a nail disorder that is increasing in prevalence worldwide. The psychological and social limitations caused by onychomycosis can potentially undermine the work and social lives of those experiencing these negative effects. This review aimed to evaluate the randomized controlled trials (RCTs) available in the current literature on the impact onychomycosis has on quality of life (QoL). Methods: A systematic review was performed using the databases PubMed, PsycINFO, Scopus, ClinicalTrials.gov, and Cochrane Library on July 18, 2017. Only RCTs with clinical effects described in English were included for review. Results: Ten RCTs reported QoL outcomes for patients suffering from onychomycosis. Treatment satisfaction was statistically significant from baseline to end of treatment in 100.0% (4/4) measures which reported on satisfaction with treatment; mental health was also significant in 100.0% (3/3), symptoms index rating in 100.0% (2/2), symptom frequency in 75.0% (3/4), overall problems in 75.0% (3/4), functional activities in 75.0% (6/8), appearance problems in 66.7% (2/3), symptom distress in 57.1% (4/7), and stigma in 40.0% (2/5). The OnyCOE-t^TM and the NailQoL were the most used common outcome measures to describe QoL. Conclusion: The study sanctions that onychomycosis physically and psychologically distresses patients’ lives. Further research should include validated outcome measures to more effectively treat onychomycosis.

show abstract

“…Patients with onychomycosis [12][13][14] and nail psoriasis [15] often feel embarrassed or stigmatized because of their disease. Such feelings are not unfounded, as shown by a recent online survey [14] , in which many respondents expressed reluctance to spend time with or be placed next to onychomycosis patients.…”

Section: Discussionmentioning

confidence: 99%

Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis

Piraccini

Starace²,

Toft³

2017

Dermatology

View full text Add to dashboard Cite

Introduction: Onychomycosis and nail psoriasis can be embarrassing to patients, so improving the appearance of affected nails should be one of the key short-term goals of treatment. Methods: An 8-week open-label multicenter study was conducted to assess whether K101-03, a marketed topical treatment containing propylene glycol, glycerol, urea, and lactic acid, could produce rapid cosmetic improvements in affected nails. Adult patients with a big toenail or thumbnail (the “target” nail) affected by onychomycosis (n = 72) or psoriasis (n = 34) or both (n = 1) applied K101-03 to their affected nails once a day for 8 weeks. During and after treatment, patients rated the overall appearance of their target nail on a 4-point scale. They also assessed whether thickening, discoloration, brittleness, and softness of the target nail had improved since baseline. Adverse events (AEs) that occurred between the first application of K101-03 and the end of treatment were recorded and categorized according to severity and relationship to K101-03. Results: After 8 weeks of K101-03 treatment, 92.2% of patients (95% confidence interval [CI] 87.06-97.40) reported at least some improvement in the target nail. After 1 week of treatment, 78.3% of patients with onychomycosis (95% CI 68.53-87.99) reported at least some improvement in the target nail, and 55.1% of them reported that discoloration of their target nail had improved. Three patients reported a total of 5 AEs, none of which were judged to be related to K101-03. Conclusions: In summary, K101-03 was well tolerated in patients with onychomycosis or nail psoriasis and rapidly improved their nails.

show abstract

Psychosocial impact of onychomycosis: a review

Cited by 34 publications

References 43 publications

Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay

Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay

The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature

Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis

Contact Info

Product

Resources

About